Novo and competitor Eli Lilly have established the market in obesity and weight loss with GLP-1s Wegovy and Zepbound, respectively
2006.07.007 Lazzaro, B.P., Zasloff, M., and Rolff, J., Science , 2020, vol
We reasoned that the systemic effects of GLP-1(9-36) might be more apparent when glucagon secretion is stimulated by insulin-induced hypoglycaemia
Effects of glucose and insulin on glucokinase activity in rat hypothalamus
Since then, others have been made, including: Liraglutide (Victoza for diabetes, Saxenda for weight loss) Dulaglutide (Trulicity), Lixisenatide (Adlyxin) Semaglutide (Ozempic, Wegovy, and Rybelsus, which is a tablet) Tirzepatide (Mounjaro and Zepbound) works on two gut hormones, not just GLP1